Published in JAMA on June 26, 2013
Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer. JAMA Oncol (2016) 4.90
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol (2014) 1.35
Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst (2014) 1.28
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol (2014) 1.13
Clinical application of genetics in management of colorectal cancer. Intest Res (2014) 1.11
Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med (2014) 1.07
Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol (2014) 1.02
Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst (2014) 1.00
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. Am J Gastroenterol (2014) 0.98
Aspirin and colorectal cancer: back to the future. Clin Cancer Res (2013) 0.95
Integration of molecular pathology, epidemiology and social science for global precision medicine. Expert Rev Mol Diagn (2015) 0.94
The role of aspirin in the prevention of cardiovascular disease. Clin Med Res (2014) 0.94
Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control (2015) 0.94
Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach. Gastroenterol Hepatol Bed Bench (2015) 0.94
Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol (2016) 0.86
Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP). Sci Rep (2015) 0.85
Differential effects of aspirin before and after diagnosis of colorectal cancer. JAMA (2013) 0.84
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer (2014) 0.83
Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut (2016) 0.83
Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet (2016) 0.83
MicroRNA MIR21 and T Cells in Colorectal Cancer. Cancer Immunol Res (2015) 0.82
Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. Gastroenterology (2016) 0.81
Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. Am J Clin Nutr (2014) 0.81
Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? Curr Colorectal Cancer Rep (2016) 0.81
Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. Br J Cancer (2015) 0.81
The effect of aspirin and nonsteroidal anti-inflammatory drug use after diagnosis on survival of oesophageal cancer patients. Br J Cancer (2016) 0.80
ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell (2015) 0.80
Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut (2015) 0.79
Risk factors for colorectal neoplasms based on colonoscopy and pathological diagnoses of Chinese citizens: a multicenter, case-control study. Int J Colorectal Dis (2014) 0.78
MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer. Cancer Immunol Res (2016) 0.78
Colorectal Cancer Epidemiology in the Nurses' Health Study. Am J Public Health (2016) 0.77
Association of Nonsteroidal Anti-Inflammatory Drugs with Colorectal Cancer by Subgroups in the VITamins and Lifestyle (VITAL) Study. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol (2016) 0.76
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst (2017) 0.76
MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Clin Cancer Res (2016) 0.76
Can Aspirin and Cancer Prevention be Ageless Companions? J Clin Diagn Res (2015) 0.76
Challenges and strategies for identifying biomarkers for colorectal cancer. Colorectal Cancer (2015) 0.75
Nonsteroidal Anti-Inflammatory Drug and Aspirin Use in Relation to Lung Cancer Risk among Postmenopausal Women. Cancer Epidemiol Biomarkers Prev (2015) 0.75
Sessile serrated polyps: detection, eradication, and prevention of the evil twin. Curr Treat Options Gastroenterol (2015) 0.75
Genomic Profiling in Gastrointestinal Cancer: Are We Ready To Use These Data to Make Treatment Decisions? Oncologist (2015) 0.75
Biomarker correlation network in colorectal carcinoma by tumor anatomic location. BMC Bioinformatics (2017) 0.75
Measures of adiposity are associated with increased risk of peptic ulcer. Clin Gastroenterol Hepatol (2014) 0.75
Tumor SQSTM1 (p62) expression and T cells in colorectal cancer. Oncoimmunology (2017) 0.75
Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. J Gastrointest Oncol (2016) 0.75
The Influence of BRAF and KRAS Mutation Status on the Association between Aspirin Use and Survival after Colon Cancer Diagnosis. PLoS One (2017) 0.75
Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype. Mod Pathol (2017) 0.75
Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor. Gastroenterology (2017) 0.75
BMI Is a Risk Factor for Colorectal Cancer Mortality. Dig Dis Sci (2017) 0.75
Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet (2010) 11.00
Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet (2007) 7.11
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med (2007) 4.74
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst (2008) 3.54
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res (2012) 3.07
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One (2008) 2.92
Colorectal cancer: a tale of two sides or a continuum? Gut (2012) 2.85
Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol (2012) 2.66
Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res (2012) 2.50
Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol (2012) 2.45
Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst (2010) 2.35
Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA (2011) 2.28
Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. J Mol Diagn (2010) 2.15
How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn (2012) 1.66
BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev (2012) 1.48
Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol (2013) 1.47
Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res (2013) 1.42
Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn (2012) 1.34
Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP). PLoS One (2011) 1.32
Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol (2012) 1.26
Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst (2012) 1.24
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study. J Pathol (2012) 1.09
Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases. Cancer Epidemiol Biomarkers Prev (2013) 1.05
Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study. Nutr Cancer (2012) 1.03
LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann Surg Oncol (2012) 1.02
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) (2011) 0.92
Nutrients in folate-mediated, one-carbon metabolism and the risk of rectal tumors in men and women. Nutr Cancer (2011) 0.92
Involvement of Ras/Raf-1/p44/42 MAPK in YC-1-induced cyclooxygenase-2 expression in human pulmonary epithelial cells. Pharmacol Res (2009) 0.82
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol (2005) 17.45
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr (2006) 10.95
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med (2007) 9.04
Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst (2004) 8.77
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst (2006) 7.19
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr (2002) 6.96
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr (2009) 5.79
A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med (2004) 5.68
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Alternative dietary indices both strongly predict risk of chronic disease. J Nutr (2012) 5.60
Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med (2006) 5.24
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Aspirin intake and survival after breast cancer. J Clin Oncol (2010) 4.50
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med (2003) 4.40
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst (2013) 4.37
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol (2006) 4.27
Serrated lesions of the colorectum: review and recommendations from an expert panel. Am J Gastroenterol (2012) 4.22
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
High school dietary dairy intake and teenage acne. J Am Acad Dermatol (2005) 4.00
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
Association of nut consumption with total and cause-specific mortality. N Engl J Med (2013) 3.94
Whole grain, bran, and germ intake and risk of type 2 diabetes: a prospective cohort study and systematic review. PLoS Med (2007) 3.91
Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA (2005) 3.88
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69